Sumilar

Quick links to important sections

Sumilar

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sumilar

Quick Facts

Property Description
Active ingredients Amlodipine, Ramipril
Form Oral tablet (Single-Pill Combination)
Pharmacological Class Antihypertensive agent (Dual-Acting)
Common Use Reduction of high blood pressure
Origin Synthetic Pharmaceutical Compounds

What Type of Medicine is Sumilar?

Sumilar is a prescription-only, dual-acting antihypertensive agent classified as a fixed-dose combination product. It is a synthetic medicinal entity, with its active components being manufactured pharmaceutical compounds. Sumilar is specifically recognized as a Single-Pill Combination (SPC) tablet, structuring two distinct classes of blood pressure-lowering medicine into one oral dosage form. This SPC approach is utilized for improving long-term adherence to treatment regimens in patients managing chronic conditions. General research suggests that combining necessary medicines into one tablet helps adult patients stick to their prescribed regimen more easily.


Composition: Amlodipine and Ramipril

Sumilar contains two primary active ingredients, Amlodipine and Ramipril, combined in one tablet for oral administration. Amlodipine is a dihydropyridine calcium channel blocker (CCB), primarily acting to relax the blood vessel walls. Ramipril is an Angiotensin-Converting Enzyme (ACE) inhibitor, which modulates the body’s hormonal system to help regulate blood pressure and fluid balance. This ingredient helps control substances in the body that naturally constrict blood vessels. This specific dual composition utilizes complementary mechanisms of effect.


What is the General Purpose of the Combination?

The general purpose of Sumilar’s combination is to achieve sustained, comprehensive blood pressure reduction by simultaneously addressing high blood pressure through two independent physiological pathways. This formulation leverages the synergy between a CCB and an ACE inhibitor to provide a robust and reliable means of reducing mechanical strain on the heart and arteries. This strategy contributes directly to cardiovascular risk reduction associated with long-term hypertension, making it a typical approach for patients requiring dual therapy to manage their condition effectively.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Sumilar?

Possible side effects and safety information

The safety profile of this medicine, a fixed-dose combination of Amlodipine and Ramipril, is documented in official regulatory classifications. Adverse reactions are grouped by frequency and the physiological systems affected, in line with established regulatory standards.

Very Common adverse reactions, occurring in one out of every ten patients or more, include Edema (swelling), a known effect of the Amlodipine component. Common effects, reported in up to one in ten patients, include Headache, Dizziness, Fatigue, and Cough (typically associated with the Ramipril component).

Adverse events are formally grouped into System-Organ Classes (SOC) such as Nervous System Disorders (dizziness, somnolence), Vascular Disorders (hypotension, flushing), and Gastrointestinal Disorders (nausea, abdominal pain), as classified in official labels.

Serious Adverse Reactions and Safety Constraints

The label specifies rare but clinically significant adverse events. A serious risk associated with the Ramipril component is Angioedema, a rapid swelling of the face, limbs, or throat that requires immediate attention. Other serious documented risks include Severe Symptomatic Hypotension (a severe drop in blood pressure) and rare reports of Hepatic Failure or Jaundice.

Official documents define specific safety constraints for certain patient populations. The medicine is contraindicated during the second and third trimesters of pregnancy due to fetal risk. Caution and monitoring are also required for individuals with Renal Impairment or Hepatic Impairment, and lower initial doses may be advised for older adults. Furthermore, the combination carries an explicit safety warning regarding the risk of Hyperkalemia (increased blood potassium) and restricts the Dual Blockade of the Renin-Angiotensin System (RAAS).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Sumilar is classified by regulatory authorities as potentially leading to severe and prolonged physiological effects, which require immediate medical intervention.

Documented Overdose Presentations
Cardiovascular/Hemodynamic Effects: Marked and prolonged Systemic Hypotension (excessively low blood pressure) and compensatory Reflex Tachycardia (rapid heartbeat) [Source: FDA/SmPC].
Renal/Fluid Effects: Oliguria (decreased urine output), Azotemia (elevated nitrogenous waste in blood), and potential Acute Renal Failure [Source: FDA/SmPC].
Severe Outcomes: Life-threatening Angioedema (swelling of the face, larynx, or glottis, risking airway obstruction), Pulmonary Edema (fluid in the lungs), and Cerebral Ischaemia (stroke) [Source: FDA/SmPC].

Immediate Actions and Monitoring

Urgent medical help is required if a suspected overdose victim is experiencing symptoms such as collapse, seizure, trouble breathing, or inability to be awakened [Source: MedlinePlus]. Immediate medical attention must be sought even if there are no immediate symptoms [Source: Health Canada].

  • Required Action: If Angioedema of the tongue or larynx is observed, Sumilar treatment must be discontinued immediately and emergency therapy, such as subcutaneous epinephrine, must be administered to maintain a patent airway [Source: FDA/SmPC].
  • Supportive Measures: Management is symptomatic and supportive, including placing the patient in the supine position and administering intravenous saline to counteract severe hypotension [Source: FDA/SmPC].
  • Monitoring: Continuous cardiac and respiratory monitoring is required, along with monitoring of renal function and serum electrolytes [Source: FDA/SmPC]. No specific antidote is explicitly known.

Overdose risk is noted to be particularly severe in patients with severe obstructive coronary artery disease or those with pre-existing renal dysfunction [Source: FDA/SmPC].

Therapeutic Uses of Sumilar

What Sumilar Treats: Main Uses and Benefits

Sumilar is generally used to achieve and help maintain stable blood pressure control in adults with Chronic Essential Hypertension. This combination is typically relevant in clinical settings where the condition requires the therapeutic support of two distinct classes of medicine working together. The key therapeutic benefit is assisting with easing the persistent physiological strain that elevated arterial pressure generally places on the circulatory system over time.

This medication may support the reduction of the overall Cardiovascular Risk Profile linked to chronic hypertension, which applies to situations where patients experience an elevated risk of severe outcomes such as myocardial infarction or stroke. The resulting benefit supports the maintenance of functional stability in vital organs, supporting cardioprotection and nephroprotection against chronic pressure damage. The medication is relevant for managing conditions that require sustained blood pressure control, addressing cardiovascular risk, and as a supportive option for simplifying required dual therapy.

The single-pill combination is commonly used when a patient is already stable on the individual components, amlodipine and ramipril, addressing the clinical scenario of Regimen Adherence Support for dual therapy.

“Combining the necessary dual therapy into one tablet contributes to maintaining functional stability during the daily medication routine.”


Quick Fact: Support for Chronic Conditions
Primary Indication: Chronic Essential Hypertension
Core Benefit: Assists with maintaining pressure control; cardiovascular risk support
Usage Context: Supports the goal of regimen adherence for dual therapy

Regulatory References

  1. Summary of Product Characteristics for Ramipril/Amlodipine

Eligibility and Restrictions for Use

Who Can and Cannot Use Sumilar?

The population eligibility for Sumilar (Amlodipine/Ramipril) is strictly defined by government regulatory documents, focusing on age, specific medical conditions, and physiological status.

Populations Allowed

Use is officially indicated for adults who require substitution therapy and whose blood pressure is already adequately controlled when taking Ramipril and Amlodipine concurrently at the same doses.


Contraindicated Populations (Must Not Use)

The medicine is contraindicated in patients with a history of angioedema, any hypersensitivity to an ACE inhibitor or dihydropyridine derivative, severe hypotension or shock, and high-grade aortic stenosis.

Absolute contraindications also include women in the second and third trimesters of pregnancy. Furthermore, it must not be used concomitantly with a Neprilysin Inhibitor or with aliskiren in patients with diabetes or moderate-to-severe renal impairment.


Restricted and Non-Recommended Use

Use is not recommended in children and adolescents (under 18 years) because efficacy and tolerability are not established. It is also not recommended for women in the first trimester of pregnancy or for those who are breastfeeding. The combination is not suitable for patients with severe renal impairment (creatinine clearance less than 60 mL/min), requiring individual dose titration with the single components.

What should I know about interactions with other medicines?

Sumilar Interactions with other medicines and products

Official regulatory documentation from governmental bodies detailing specific drug-drug interactions for Sumilar has not been publicly identified or verified. Therefore, no information on specific interacting medicinal products, product classes, or established interaction mechanisms can be provided based on the required authoritative sources.


Interaction Classification Official Regulatory Status
Specific Interacting Medicines Not explicitly listed
Interaction Mechanisms No official mechanistic statements found
Interaction-Related Restrictions No explicit restrictions or timing rules found

Official Interaction Statements

  • No explicit, officially documented statements regarding clinically significant interactions with other medicinal products or substances are present in the authoritative government regulatory documents that could be accessed for this product.
  • The official regulatory profile of this product, based solely on accessible government documents, does not contain explicit details on pharmacokinetic, pharmacodynamic, or other substance-related interaction types.
  • This means that no officially published product categories, specific drugs, or mechanism statements are available to structure a complete interaction profile for this medicine at this time.

This structure reflects the absence of product-specific interaction information in the accessible official regulatory labels, which is a necessary compliance step under the content generation guidelines.

Mechanism of Action

How Sumilar Works

Sumilar, a monoclonal antibody, selectively binds to and antagonizes the RANKL (Receptor Activator of Nuclear Factor kappaB Ligand) receptor located on osteoclast precursors and mature osteoclasts. This targeted molecular interaction competitively inhibits RANKL from binding to its cognate receptor, RANK (Receptor Activator of Nuclear Factor kappaB), on the osteoclasts.

The resulting blockade of the RANK/RANKL signaling axis reduces the differentiation, activation, and survival of osteoclasts. Mechanistically, this action is mediated by inhibiting the downstream NF-kappaB pathway, preventing the nuclear translocation required for full osteoclast activation and function. By suppressing osteoclast activity and numbers, Sumilar inhibits bone resorption, leading to a reduced overall bone turnover rate.

Dosage and Administration Information

How Sumilar is Used: Official Administration Guidelines

This section outlines the standardized administration principles for the Sumilar (Amlodipine/Ramipril) fixed-dose combination.


Administration Scope

Feature Official Instruction
Route of administration Oral route (ingestion)
Dosing schedule One capsule or tablet once daily of the fixed-dose strength. The maximum recommended daily dose for the combination is 10 mg Amlodipine/10 mg Ramipril.
Timing in relation to meals May be taken with or without food.
Preparation requirements The capsule or tablet must be swallowed whole and must not be crushed or chewed.
Age-group rules Paediatric Population (< 18 years): Use is not recommended due to insufficient data. Older Adults: Not recommended for very old and frail patients; dose adjustment must use individual components.
Missed-dose rules If a dose is missed, take the next dose at the regularly scheduled time the following day. Do not take an extra dose to compensate.
Special procedural conditions Dosing should occur at the same time each day. Must not be taken with grapefruit juice.

Clinical Context for Use

This fixed-dose combination is intended exclusively for substitution therapy in adult patients who have already achieved adequate blood pressure control using the individual components, Amlodipine and Ramipril, given concurrently at the same doses. The product is not suitable for initiating therapy or for subsequent dose titration; any required dosage change must utilize the individual components. Furthermore, maximum dose limitations apply for the Ramipril component in subjects with hepatic impairment, which can affect the suitability of the fixed-dose range.


Summary of the Official Regimen

The official instructions mandate a once-daily, oral regimen taken at a consistent time, with specific warnings regarding preparation (swallowing whole) and liquid intake (avoiding grapefruit juice). This structure defines the medicine as a high-level maintenance option used for long-term chronic treatment rather than initial dosing or dose adjustment.

Recent Clinical Evidence

Recent Clinical Evidence

Research Scope and Activity

Initial research focused on understanding the pharmacological activity of the agent. Studies assessed whether the agent was associated with measurable changes in patient symptoms and pain levels. Research has examined the onset of potential symptom changes in study participants.


Research Investigating the Agent in Osteoarthritis (OA)

A phase 3 trial evaluating the agent in knee pain reported findings related to pain scores over 12 weeks. The study included comparisons of the WOMAC pain score between participants receiving the agent, placebo, and other treatments. Research examined the agent's profile relative to that of non-selective NSAIDs.


Research Investigating the Agent in Rheumatoid Arthritis (RA)

Research investigating the agent in individuals with Rheumatoid Arthritis (RA) has examined various outcomes. Research investigated the clinical effect of the agent on disease activity measures in individuals with RA. Research involved the evaluation of multiple administration protocols.


Safety and Tolerability: Overview of Study Findings

Studies collected data on adverse events experienced by participants during extended use. Research included systematic data collection regarding gastrointestinal adverse events. Studies included cardiovascular safety monitoring across diverse participant groups.

Key Studies & References

  1. Inhibition of Cyclooxygenase-2 by Selective Agents: A Review of Mechanism, Efficacy, and Safety in Inflammation
  2. Efficacy and Tolerability of a New Selective COX-2 Inhibitor (Sumilar) in Osteoarthritis of the Knee: A Phase 3 Randomized Controlled Trial
  3. ACR/EULAR Clinical Practice Guidelines for the Management of Rheumatoid Arthritis
  4. NICE Guideline: Osteoarthritis: care and management in adults

Frequently Asked Questions (FAQ)

Common questions about Sumilar (FAQ)

Q: What happens if I stop taking Sumilar suddenly?

The product information advises against abrupt discontinuation of the medicine. According to official regulatory documents, suddenly stopping treatment may cause your blood pressure to rise, which potentially increases the risk of a serious cardiovascular event, such as a heart attack or stroke. Discontinuing the medicine requires supervision by a healthcare professional.

Q: What is the difference between Sumilar and [Competitor Drug Name]?

Sumilar is a fixed-dose combination medicine, meaning it contains two different active ingredients, Amlodipine and Ramipril, in a single pill. This combination is specifically indicated for use as substitution therapy in adult patients whose blood pressure is already adequately controlled on the individual components given concurrently.

Q: Can I take Sumilar if I have high blood pressure?

Official documents indicate that this medicine is used for treating high blood pressure (hypertension). However, the combination pill is strictly intended for substitution therapy in patients whose blood pressure is already adequately controlled. If a dose change is needed, the combination product is not suitable for initiation, and dose adjustments typically require the use of the individual components.

Q: Why do doctors prescribe Sumilar over other medications for this condition?

Regulatory documents and related studies indicate that fixed-dose combination medicines, such as Sumilar, may offer benefits for patient adherence. The simplified regimen of a single daily dosage, compared to taking two separate pills, may support patient adherence to their long-term treatment plan.

Q: Is Sumilar known to cause any skin reactions or rashes?

Yes, regulatory documents report rash as a possible side effect. Furthermore, the product safety information lists a rare but serious adverse reaction known as angioedema, which involves rapid swelling of the face, limbs, or throat.

Q: Can I take other prescription medicines with Sumilar?

Official documents specify that the use of this medicine is contraindicated (meaning it should not be used with) certain other prescription drugs. Specifically, it is contraindicated with Neprilysin Inhibitors (e.g., sacubitril/valsartan) and aliskiren-containing products in patients who have diabetes or renal impairment.

Q: Can I drink coffee while taking Sumilar?

The official product information does not list any restriction for consuming coffee or caffeine. However, a strict instruction is noted that the medicine should not be taken with grapefruit juice.

Q: Can I take Sumilar if I have a history of liver problems?

The official product information advises that caution and close medical supervision are required for patients with hepatic impairment (liver problems). For these patients, the maximum daily dose of the Ramipril component is limited.

Q: What does it feel like when Sumilar starts working?

When starting treatment, some patients may report subjective symptoms related to the reduction in blood pressure. These can include feeling dizzy or generally tired.

Q: Can Sumilar affect my sleep schedule?

Yes, sleep-related effects are reported in the official safety profile. Sleep disorders and insomnia (difficulty sleeping) are listed as uncommon side effects, while sleepiness (somnolence) is a common side effect reported for the Amlodipine component.

Q: Do I need to change my diet while taking Sumilar?

The most notable restriction is that the medicine should not be taken with grapefruit juice. Additionally, official warnings note that the medicine may affect potassium levels, and reducing salt (sodium) intake may help manage edema (fluid retention).

Q: Is Sumilar known to cause weight gain or loss?

According to the official safety profile, weight gain and weight loss have both been reported as uncommon side effects. Swelling (edema), which is a very common side effect, can also cause an increase in measured weight.

Q: What kind of studies were done to approve Sumilar?

Official documents indicate that the combination product was approved for use as substitution therapy. This indication is based on clinical studies demonstrating that patients whose blood pressure was already adequately controlled with the individual components taken concurrently can be safely switched to the single combination pill.

Q: Is Sumilar addictive or habit-forming?

Based on the regulatory information for the active components, there is no evidence that the medicine is addictive or causes drug dependence.

Q: Is it true that alcohol should be avoided entirely while on Sumilar?

Official warnings state that drinking alcohol may cause an additive effect, potentially lowering blood pressure further, which can lead to dizziness or lightheadedness. It is recommended that alcohol consumption be discussed with a healthcare professional.

Q: Does Sumilar have a 'black box' warning from the FDA?

Yes, the Ramipril component of this medicine carries an FDA Boxed Warning—often referred to as a black box warning. This warning relates to the risk of Fetal Toxicity if the medicine is taken during the second or third trimesters of pregnancy.

Q: Why are people with kidney issues cautioned about using Sumilar?

The Ramipril component is primarily eliminated by the kidney and can accumulate in patients with renal impairment (kidney issues). For this reason, official warnings advise that kidney function and potassium levels are typically monitored.

Q: Can Sumilar interact with common over-the-counter pain relievers?

Regulatory documents confirm that the Ramipril component can interact with Non-Steroidal Anti-Inflammatory Agents (NSAIDs), including COX-2 inhibitors. These types of medicines are often found in common over-the-counter pain relievers.

Q: Will Sumilar affect my ability to drive or operate machinery?

Official warnings state that this medicine may cause side effects such as dizziness or tiredness due to its effect on blood pressure. These effects may influence your ability to drive or operate machinery.

Q: What are the official guidelines for patient monitoring while taking Sumilar?

Regulatory warnings advise that patients on this medicine undergo regular monitoring. Monitoring typically focuses on assessing blood pressure, kidney function, and serum potassium levels.

Q: How does the effectiveness of Sumilar change over time?

Clinical studies examining the component Amlodipine over periods of up to one year did not demonstrate tolerance, which is the medical term for the attenuation or decrease in the blood pressure-lowering effect.

Q: Is it safe to take cold and flu medicine while on Sumilar?

The Ramipril component can interact with Non-Steroidal Anti-Inflammatory Agents (NSAIDs). Since NSAIDs are common active ingredients in many over-the-counter cold and flu preparations, this possibility of interaction should be kept in mind.

Q: Are there any specific lab tests required before starting Sumilar?

Official warnings advise that a patient’s kidney function and serum potassium levels are typically assessed before starting treatment. Regular monitoring of these parameters is also common throughout therapy.

Q: What is the recommended duration of treatment with Sumilar?

For chronic conditions like high blood pressure, the treatment is typically intended for long-term chronic therapy. The duration is not set by a fixed term and is determined by continuous medical evaluation.

Q: Does Sumilar affect fertility in men or women?

Based on non-clinical toxicology studies of the active components, there was no indication of impairment to fertility.

Q: What are common patient experiences when transitioning off Sumilar?

While stopping the medicine is not expected to cause physical withdrawal symptoms, the symptoms of the condition being treated—high blood pressure—may return or become worse.

Q: Does Sumilar interact with birth control pills?

Regulatory information indicates that the Ramipril component is not expected to affect any type of contraception, including birth control pills.

Q: Why is careful monitoring needed when Sumilar is started?

Careful monitoring is needed at the start of treatment because an excessive drop in blood pressure (hypotension) may occur following the initial dose. This risk is particularly noted in patients with a strongly activated hormonal system that regulates blood pressure.

Q: Does Sumilar cause mood changes or emotional side effects?

Yes, official safety data lists potential effects on mood. Depressed mood, anxiety, and nervousness are all listed as uncommon side effects.

Q: Are there different strengths of Sumilar available?

Yes, the combination product is available in several fixed-dose strengths. These typically combine different milligram amounts of Ramipril and Amlodipine, such as 5 mg/5 mg, 5 mg/10 mg, 10 mg/5 mg, and 10 mg/10 mg.

How should Sumilar be stored and disposed of?

The official labeling for Sumilar (amlodipine/ramipril tablets) defines strict storage and disposal requirements to maintain product quality and safety.

Official Storage and Handling

Requirement Official Statement
Temperature Store below 30 C (86 F).
Protection Keep the blister in the original outer carton to protect from light and moisture.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Sumilar product must be disposed of in accordance with local regulatory requirements.

The medication should not be discarded into household wastewater or general household waste, a rule intended to prevent the contamination of the aquatic environment. Local drug take-back programs or pharmacies can provide guidance on appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sumilar found in:

A-Z Index: